Last updated: March 9, 2026
What is NDC 70000-0480 and its Current Market Position?
NDC 70000-0480 is the code for Sotorasib (Zeposia), a targeted therapy approved for specific oncology indications. It primarily treats non-small cell lung cancer (NSCLC) with KRAS G12C mutation. Launched in December 2021 by Amgen, Sotorasib is the first selective KRAS G12C inhibitor approved by the FDA.
As a recently introduced medication, Sotorasib has captured a niche segment in oncology, competing with other targeted therapies for advanced NSCLC. Its unique mechanism and FDA approval status position it as a leading option, but market penetration remains in early phases due to exclusivity rights and competitive dynamics.
Market Size and Penetration
Target Patient Population
Estimated NSCLC patients with KRAS G12C mutations in the U.S.: approximately 13,000 annually (based on prevalence of approximately 13% among NSCLC cases, with total NSCLC cases around 120,000 per year) [1].
Market Share Trends
- Initial launch year (2022): Small adoption, primarily through specialized oncology centers.
- 2023 forecasts: Incremental increase in prescribing, with gradual expansion into broader patient populations.
- Market penetration projected to reach 25-30% of eligible patients within five years [2].
Pricing Benchmarking
- List price (2018-2022): Approximately $17,000 per month (estimated retail price).
- Actual net price influenced by rebates, discounts, and insurance negotiations.
Price Projections
Short-Term (Next 1-2 Years):
- List price remains stable at about $17,000/month.
- Discounted net price likely to average $13,000–$15,000/month, based on payor negotiations and rebates.
Mid-Term (3-5 Years):
- Due to increasing market penetration and expanded indications, list prices may slightly increase, up to $18,500/month.
- Competition, potential biosimilars, or subsequent KRAS inhibitors could pressure prices downward, leading to net prices around $14,000–$16,000/month.
Long-Term (Beyond 5 Years):
- Price stabilization expected, with subtle adjustments for inflation.
- If biosimilar or alternative therapies gain significant market share, prices could decline by 10-20% over a decade.
Competitive Dynamics
| Competitor |
Year of Approval |
Price Range |
Market Share |
Notes |
| Sotorasib |
2021 |
$17,000/month |
Growing |
First KRAS G12C inhibitor |
| Amgen's Lumakras |
2021 |
$17,000/month |
Growing |
Market leader in KRAS G12C |
| Adagrasib |
2022 |
~$16,500/month |
Emerging |
Pending approval for expanded uses |
The rapid development and approval of alternatives might challenge Sotorasib’s pricing power.
Regulatory and Policy Influences
- Price regulation pressure: Increasing debate regarding drug affordability influences future pricing.
- Medicare and private insurance negotiations could restrict payable prices, especially if biosimilars or generics enter the market.
Price Outlook Summary
| Year |
Estimated List Price |
Estimated Net Price |
Market Penetration |
Notes |
| 2023 |
$17,000 |
$13,000–$15,000 |
10–15% |
Stable prices, limited access |
| 2025 |
$18,000 |
$14,000–$16,000 |
25–30% |
Slight price increase |
| 2030 |
$18,500 |
$14,500–$17,000 |
50–60% |
Market saturation, discounts |
Key Market Drivers
- Efficacy and safety profile of Sotorasib in KRAS G12C mutation NSCLC.
- Insurance coverage and rebate strategies.
- Expansion of indications and real-world evidence.
- Competitive landscape evolution.
Final Remarks
Sotorasib’s market prospects depend heavily on clinical adoption, biosimilar competition, and policy developments. Expect list prices to increase modestly over the next five years, with net prices reflecting negotiations and payer strategies.
Key Takeaways
- Sotorasib (NDC 70000-0480) targets a niche but growing segment within NSCLC therapy.
- Pricing remains stable but subject to pressure from competitors and policy changes.
- Early-stage market penetration limits immediate revenue but promises growth.
- Prices projected to rise slightly to around $18,500/month by 2025.
- Competitive dynamics and biosimilar development could reduce prices in the longer term.
FAQs
1. What factors influence Sotorasib’s pricing?
Clinical efficacy, payer negotiations, competitor activity, and policy regulations.
2. How much market share can Sotorasib expect in five years?
Approximately 25-30% of eligible KRAS G12C NSCLC patients.
3. Are biosimilars expected for Sotorasib?
Potentially, if patent protections expire or if alternative therapies approved, which could lower prices.
4. How does Sotorasib’s price compare internationally?
Most markets mirror initial U.S. pricing but are subject to local regulation, potentially resulting in lower prices outside the U.S.
5. What is the impact of expanding indications on pricing?
Broader indications could increase volume, providing opportunities for price negotiations to stabilize or raise prices.
References
- American Cancer Society. (2022). Cancer facts & figures 2022. https://www.cancer.org
- IQVIA. (2022). Prescription drug market analysis.
